Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines

Laboratory of Veterinary Pathology, Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan. .
BMC Veterinary Research (Impact Factor: 1.78). 07/2012; 8(1):128. DOI: 10.1186/1746-6148-8-128
Source: PubMed


Canine hemangiosarcoma (HSA) is a malignant tumor with poor long-term prognosis due to development of metastasis despite aggressive treatment. The phosphatidyl-inositol-3 kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is involved in its endothelial pathologies; however, it remains unknown how this pathway plays a role in canine HSA. Here, we characterized new canine HSA cell lines derived from nude mice-xenografted canine HSAs and investigated the deregulation of the signaling pathways in these cell lines.
Seven canine HSA cell lines were established from 3 xenograft canine HSAs and showed characteristics of endothelial cells (ECs), that is, uptake of acetylated low-density lipoprotein and expression of canine-specific CD31 mRNA. They showed varied morphologies and mRNA expression levels for VEGF-A, bFGF, HGF, IGF-I, EGF, PDGF-B, and their receptors. Cell proliferation was stimulated by these growth factors and fetal bovine serum (FBS) in 1 cell line and by FBS alone in 3 cell lines. However, cell proliferation was not stimulated by growth factors and FBS in the remaining 3 cell lines. Phosphorylated p44/42 Erk1/2 was increased by FBS stimulation in 4 cell lines. In contrast, phosphorylation of Akt at Ser473, mTOR complex 1 (mTORC1) at Ser2448, and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) at Ser65 was high in serum-starved condition and not altered by FBS stimulation in 6 cell lines, despite increased phosphorylation of these residues in normal canine ECs. This suggested that the mTORC2/Akt/4E-BP1 pathway was constitutively activated in these 6 canine HSA cell lines. After cell inoculation into nude mice, canine HSA tumors were formed from 4 cell lines and showed Akt and 4E-BP1 phosphorylation identical to the parental cell lines.
Our findings suggest that the present cell lines may be useful tools for investigating the role of the mTORC2/Akt/4E-BP1 pathway in canine HSA formation both in vivo and in vitro.

Download full-text


Available from: Atsushi Kodama, Dec 17, 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the effects of phosphatidylinositol 3 kinase-protein kinase B (PI3K-AKT) signal pathway on the proliferation, apoptosis and invasiveness of colon cancer cell line SW480 and explore its possible mechanisms. SW480 cells were cultured with various concentrations (0, 5, 10, 20 and 40 µmol/L) of LY294002 and methyl thiazolyl tetrazolium (MTT) assay was conducted after 24, 48 and 72 hours. SW480 cells were cultured for 24 hours with various concentrations (0, 10, 20 and 40 µmol/L) of LY294002. The apoptotic rate was measured by flow cytometry (FCM). The difference of invasiveness was examined by Transwell invasion test. Western blotting was used to examine the expressions of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9). One-way ANOVA was used for statistical analysis. MTT assay showed that the proliferation rate of all SW480 cells except for the lowest concentration group (5 µmol/L) was lower than the control group (0 µmol/L) and a time-dosage dependence existed (all P < 0.05). The results of FCM demonstrated that the apoptotic rates of 10, 20 and 40 µmol/L groups were 13.3% ± 0.9%, 30.9% ± 2.5% and 41.2% ± 4.1% respectively, and were all significantly higher than control group (5.2% ± 1.8%, all P < 0.05). The number of cells penetrating through the membrane of 10, 20 and 40 µmol/L groups were 87 ± 6, 65 ± 7 and 46 ± 11 respectively. All invasiveness groups were all lower than control group (100 ± 10, all P < 0.05) except the 10 µmol/L concentration group (P = 0.096). Western blotting showed that the expressions of VEGF and MMP-9 were all lower than control group (all P < 0.05). PI3K-AKT signal pathway plays an important role in the proliferation, apoptosis and inhibition of colonic cancer cells. Its mechanism is probably related with the inhibitions of VEGF and MMP-9. PI3K-AKT signal pathway may become a potential target for the treatment of colon cancer.
    No preview · Article · Feb 2013 · Zhonghua yi xue za zhi
  • Article: Sarcomas
    [Show abstract] [Hide abstract]
    ABSTRACT: Sarcomas, as opposed to carcinoma, are rare forms of human cancer comprising less than 1∈% of adult cancers. While represented by a broad range of entities, sarcomas share a common ground that is a mesenchymal origin of the tumors. With the understanding of these various types of sarcomas at the molecular level recently gaining its momentum, the role of translation in the pathobiology of this group of diseases started to uncover, pointing at a common theme: the activation of the mTOR pathway with subsequent derepression of the function of eIF4E via 4E-BPs and the activation of the proproliferative translation program. In this chapter, we, for the first time, summarize the current knowledge regarding translation, its regulation, as well as diagnostic and therapeutic potential in various types of sarcomas. © 2014 Springer Science+Business Media Dordrecht. All rights reserved.
    No preview · Article · Mar 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sarcomas encompass a heterogenous group of tumors with diverse pathologically and clinically overlapping features. It is a rarely curable disease, and their management requires a multidisciplinary team approach. Chronic inflammation has emerged as one of the hallmarks of tumors including sarcomas. Classical inflammation-associated sarcomas comprise the inflammatory malignant fibrous histiocytoma and Kaposi sarcoma. The identification of specific chromosomal translocations and important intracellular signaling pathways such as Ras/Raf/MAPK, insulin-like growth factor, PI3K/AKT/mTOR, sonic hedgehog and Notch together with the increasing knowledge of angiogenesis has led to development of targeted therapies that aim to interrupt these pathways. Innovative agents like oncolytic viruses opened the way to design new therapeutic options with encouraging findings. Preclinical evidence also highlights the therapeutic potential of anti-inflammatory nutraceuticals as they can inhibit multiple pathways while being less toxic. This chapter gives an overview of actual therapeutic standards, newest evidence-based studies and exciting options for targeted therapies in sarcomas.
    No preview · Article · May 2014 · Advances in Experimental Medicine and Biology
Show more